Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB2015-LR trial in low- and intermediate-risk neuroblastoma
2024-517295-37-00Phase 3Authorised
- Sponsor
- University of Cologne
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cyclophosphamide, cisplatin, etoposide, ifosfamide, doxorubicin and 5 more in neuroblastoma (4 arms), sponsored by University of Cologne. Primary endpoint: Event-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
cyclophosphamidecisplatinetoposideifosfamidedoxorubicin
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2024-517295-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517295-37-00.